“…It appears from published reports that serum N-terminal PTH levels are useful in discriminating between healthy subjects and hyperparathyroid patients (6,7,8,3,9,10) in venous catheterization studies for localization of parathyroid tissue (11), hypercalcaemic secondary hyperparathyroidism, chronic renal failure, and in the investigation of the pharmacokinetics of exogenously administered hPTH (1-34) (12,13). However, from the view point of reliability and sensitivity the current N-terminal PTH immunoassays based on polyclonal antibodies are far from adeguate for this purpose (14).…”